JMP Securities Reiterates Market Outperform on Blueprint Medicines, Maintains $114 Price Target
Portfolio Pulse from Benzinga Newsdesk
JMP Securities analyst Reni Benjamin has reiterated a Market Outperform rating on Blueprint Medicines (NASDAQ:BPMC), maintaining a price target of $114.
February 16, 2024 | 7:36 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Blueprint Medicines maintains a Market Outperform rating and a $114 price target from JMP Securities.
The reiteration of a Market Outperform rating and a significant price target of $114 by JMP Securities suggests a strong confidence in Blueprint Medicines' future performance. This endorsement is likely to instill positive sentiment among investors, potentially driving up the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90